Immuneering Announces Participation in March Investor Conferences
February 28 2023 - 8:00AM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company developing medicines for broad populations of cancer
patients with an initial aim to develop a universal-RAS therapy,
today announced that management will participate in two March
investor conferences to share commentary around the company’s
pipeline, platform, and business strategy. Participating will be
Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott
Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief
Scientific Officer, and Mallory Morales, CPA, Vice President of
Finance, Treasurer.
Immuneering will participate in the following investor
conferences:
Cowen 43rd Annual Health Care Conference (March 6 – 8,
2023)Format: Panel Discussion and 1x1 Investor
MeetingsPanel Discussion: Titled ‘Targeted Oncology’ on March 7
from 2:10 to 3:10 p.m. ET
Oppenheimer 33rd Annual Healthcare Conference (March 13
– 15, 2023) Format: Virtual Presentation and 1x1 Investor
Meetings Virtual Presentation: March 14 from 2:40 to 3:10 p.m.
ET
The presentations will be webcast live and
archived for 90 days in the Investor Relations section of
Immuneering’s website at Events & Presentations.
About Immuneering
Corporation
Immuneering is a clinical-stage oncology company
developing medicines for broad populations of cancer patients with
an initial aim to develop a universal-RAS therapy. The company aims
to achieve universal activity through deep cyclic inhibition of the
MAPK pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a
study in patients with advanced solid tumors harboring RAS
mutations. The company’s development pipeline also includes
IMM-6-415, which is designed to have an accelerated cadence
relative to IMM-1-104, as well as several early-stage programs. For
more information, please visit www.immuneering.com
Media Contact:Gina NugentNugent
Communications617-460-3579gina@nugentcommunications.com
Investor Contact:Laurence WattsGilmartin
Group619-916-7620laurence@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024